These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

331 related items for PubMed ID: 17414683

  • 1. Medication adherence and the use of long-acting antipsychotics in bipolar disorder.
    El-Mallakh RS.
    J Psychiatr Pract; 2007 Mar; 13(2):79-85. PubMed ID: 17414683
    [Abstract] [Full Text] [Related]

  • 2. Depot antipsychotic medications in bipolar disorder: a review of the literature.
    Bond DJ, Pratoomsri W, Yatham LN.
    Acta Psychiatr Scand Suppl; 2007 Mar; (434):3-16. PubMed ID: 17688458
    [Abstract] [Full Text] [Related]

  • 3. Adherence and assured administration of medications in bipolar patients.
    El-Mallakh PL, El-Mallakh RS.
    Curr Drug Deliv; 2013 Dec; 10(6):706-12. PubMed ID: 24033263
    [Abstract] [Full Text] [Related]

  • 4. Treatment adherence with antipsychotic medications in bipolar disorder.
    Sajatovic M, Valenstein M, Blow FC, Ganoczy D, Ignacio RV.
    Bipolar Disord; 2006 Jun; 8(3):232-41. PubMed ID: 16696824
    [Abstract] [Full Text] [Related]

  • 5. Antidepressants and antipsychotics in the long-term treatment of bipolar disorder.
    Kusumakar V.
    J Clin Psychiatry; 2002 Jun; 63 Suppl 10():23-8. PubMed ID: 12392350
    [Abstract] [Full Text] [Related]

  • 6. [French Society for Biological Psychiatry and Neuropsychopharmacology task force: Formal Consensus for the prescription of depot antipsychotics].
    Samalin L, Abbar M, Courtet P, Guillaume S, Lancrenon S, Llorca PM.
    Encephale; 2013 Dec; 39 Suppl 4():189-203. PubMed ID: 24373464
    [Abstract] [Full Text] [Related]

  • 7. A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia.
    Bhanji NH, Chouinard G, Margolese HC.
    Eur Neuropsychopharmacol; 2004 Mar; 14(2):87-92. PubMed ID: 15013023
    [Abstract] [Full Text] [Related]

  • 8. Review of treatments that can ameliorate nonadherence in patients with schizophrenia.
    Kane JM.
    J Clin Psychiatry; 2006 Mar; 67 Suppl 5():9-14. PubMed ID: 16822091
    [Abstract] [Full Text] [Related]

  • 9. Patients' reports of the factors influencing medication adherence in bipolar disorder - an integrative review of the literature.
    Crowe M, Wilson L, Inder M.
    Int J Nurs Stud; 2011 Jul; 48(7):894-903. PubMed ID: 21481391
    [Abstract] [Full Text] [Related]

  • 10. A long-term prospective study on the outcome of bipolar patients treated with long-acting injectable risperidone.
    Vieta E, Nieto E, Autet A, Rosa AR, Goikolea JM, Cruz N, Bonet P.
    World J Biol Psychiatry; 2008 Jul; 9(3):219-24. PubMed ID: 18609430
    [Abstract] [Full Text] [Related]

  • 11. Enhancing medication adherence in patients with bipolar disorder.
    Berk L, Hallam KT, Colom F, Vieta E, Hasty M, Macneil C, Berk M.
    Hum Psychopharmacol; 2010 Jan; 25(1):1-16. PubMed ID: 20041478
    [Abstract] [Full Text] [Related]

  • 12. Relapse and rehospitalization: comparing oral and depot antipsychotics.
    Schooler NR.
    J Clin Psychiatry; 2003 Jan; 64 Suppl 16():14-7. PubMed ID: 14680414
    [Abstract] [Full Text] [Related]

  • 13. Use of long-acting risperidone in psychiatric disorders: focus on efficacy, safety and cost-effectiveness.
    Keith S.
    Expert Rev Neurother; 2009 Jan; 9(1):9-31. PubMed ID: 19102665
    [Abstract] [Full Text] [Related]

  • 14. Evolving trends in the long-term treatment of bipolar disorder.
    Vieta E, Rosa AR.
    World J Biol Psychiatry; 2007 Jan; 8(1):4-11. PubMed ID: 17366344
    [Abstract] [Full Text] [Related]

  • 15. Depot risperidone in the outpatient management of bipolar disorder: a 2-year study of 10 patients.
    Malempati RN, Bond DJ, Yatham LN.
    Int Clin Psychopharmacol; 2008 Mar; 23(2):88-94. PubMed ID: 18301123
    [Abstract] [Full Text] [Related]

  • 16. Approaches to preventing relapse in bipolar disorder: addressing nonadherence and prodromal symptoms.
    Swann AC.
    J Clin Psychiatry; 2010 Dec; 71(12):e35. PubMed ID: 21190635
    [Abstract] [Full Text] [Related]

  • 17. What is the evidence for the use of second-generation antipsychotic long-acting injectables as maintenance treatment in bipolar disorder?
    Samalin L, Nourry A, Charpeaud T, Llorca PM.
    Nord J Psychiatry; 2014 May; 68(4):227-35. PubMed ID: 23795859
    [Abstract] [Full Text] [Related]

  • 18. Strategies for dosing and switching antipsychotics for optimal clinical management.
    Buckley PF, Correll CU.
    J Clin Psychiatry; 2008 May; 69 Suppl 1():4-17. PubMed ID: 18484804
    [Abstract] [Full Text] [Related]

  • 19. Factors that affect adherence to bipolar disorder treatments: a stated-preference approach.
    Johnson FR, Ozdemir S, Manjunath R, Hauber AB, Burch SP, Thompson TR.
    Med Care; 2007 Jun; 45(6):545-52. PubMed ID: 17515782
    [Abstract] [Full Text] [Related]

  • 20. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J.
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.